

October 25<sup>th</sup>, 2018

SCM LIFESCIENCE AND CCM DUOPHARMA BIOTECH BERHAD ANNOUNCE  
EQUITY INVESTMENT FOR STEM CELL PLATFORM TECHNOLOGY AND  
DEVELOPMENT PROGRAM



[The Picture of Signing Ceremony of October 25<sup>th</sup>]

▲ From the left, Dr. BG Rhee, CEO of SCM Lifescience and Mr. Leonard Ariff Abdul Shatar, Group Managing Director of CCM Duopharma Biotech Berhad

SCM Lifescience Co., Ltd. and CCM Duopharma Biotech Berhad announced that they have entered into an equity investment agreement on October 25<sup>th</sup>, 2018. Based on this agreement, SCM Lifescience will receive US \$5 million investment from CCM Duopharma Biotech Berhad, a leading pharmaceutical manufacturer in Malaysia.

SCM Lifescience specializes in stem cell therapeutics with proprietary platform technology in the field of high-purity isolation and cultivation of mesenchymal stem cells. SCM currently focuses on autoimmune diseases such as chronic and acute graft-versus-host disease (GVHD), severe acute pancreatitis, severe atopic dermatitis, and severe liver cirrhosis. The company reported that it has recently raised US \$35 million through series C funding last August. Including CCM Duopharma Biotech Berhad's equity investment, SCM Lifescience have raised a total of US \$40 million, with US \$7 million in foreign investment alone.

This investment agreement has laid the groundwork for the penetrating southeastern Asia market and could provide a driving force for global expansion of SCM Lifescience.

Dr. BG Rhee, the CEO of SCM Lifescience said, "This agreement recognizes the value of SCM Lifescience's platform technology for stem cell therapeutics. The equity investment and collaboration between SCM Lifescience and CCM Duopharma Biotech Berhad is expected to be of great help to targeting the global market."

Mr. Leonard Ariff Abdul Shatar, the Group Managing Director of CCM Duopharma mentioned, "CCM Duopharma has been looking very closely at potential strategic investments in regenerative medicines as well as stem cells. This is in line with CCM Duopharma's strategy to enter niche areas which will enable the company to boost its revenue and gain early access to the technology."

### **About SCM**

SCM Lifescience is a research-based biopharmaceutical company focused on developing next-generation stem cell therapeutics for difficult-to-treat autoimmune diseases. It has a robust pipeline in clinical and pre-clinical stages based on its proprietary platform technologies for isolating and manufacturing adult mesenchymal stem cells. Through over 10 years of R&D, SCM Lifescience has obtained intellectual property protection for its high-purity stem cell isolation technology and subfractionation culturing method in major countries including the US, EU, Japan and China.

SCM is headquartered in Incheon, Republic of Korea. <http://www.scmlifescience.com>

### **About CCM Duopharma Biotech Berhad**

CCM Duopharma is engaged in the development, manufacturing and marketing of generic drugs and branded healthcare products. It is the leading pharmaceutical manufacturer in Malaysia and a key regional player that offers a wide range of products in the form of tablets, capsules, syrup, oral antibiotic, creams, hemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges and eye drop preparations.

Its portfolio of products supports wellness for every stage of life from prevention to treatment and cure. It produces over 200 generic drugs, including the award-winning medications such as Omesec and Vascor whilst its Over-The-Counter brands such as Champs, Flavettes, Proviton and Uphamol are well recognised and accepted by consumers in Malaysia and regionally.

It is the first pharmaceutical company to receive the Halal Pharmaceuticals Certification based on the world's first Halal Pharmaceuticals Standard: MS2424:2012 "Halal Pharmaceuticals - General Guidelines" and also listed in the Malaysia Book of Records in 2013.